KR20220103849A - Compositions comprising phlorotannin for improving motor function - Google Patents

Abstract

The present invention relates to a composition having an effect of improving athletic function by comprehensively improving the function of a musculoskeletal system through oral ingestion. More specifically, the present invention relates to a composition comprising a phlorotannin compound as an active ingredient, and related products, which can be ingested in a beverage form to comprehensively improve bone density, bone mass, flexibility, and equilibrioception, and thus can be used to contribute to increasing the quality of living, sports, and artistic activity that essentially require the successful functioning of the musculoskeletal system.

Description

Composition for improving motor function comprising phlorotannin as an active ingredient {COMPOSITIONS COMPRISING PHLOROTANNIN FOR IMPROVING MOTOR FUNCTION}

The present invention relates to a composition for improving motor function of humans, particularly those aged 60 years or older, and a product comprising the same, and to a composition comprising a specific combination of Eccol-based compounds and having an effect of improving reduced motor function and a product comprising the same it's about

The human musculoskeletal system is a system that enables human movement. Anatomically, it consists of bones, muscles, cartilage, ligaments, etc., and exists as a system integrated throughout the human body through the vascular system, the nervous system and the immune system. do.

Various organs such as the heart are very important in the human body, but without the musculoskeletal system, physical forces such as earth's gravity cannot be overcome. do. Therefore, the health of the musculoskeletal system is an essential element of life that enables humans to live independently. Through a healthy musculoskeletal system, body protection, dynamic function and beauty can be made possible by controlling the magnitude and strength of the movement of the extremities and performing flexible and balanced movements. In other words, the normal functioning of the musculoskeletal system is absolutely important for survival and human dignity, as well as physical beauty, athletics and artistic dimensions.

In many cases, except for cases where the musculoskeletal system is impaired due to trauma, it is recovered by appropriate surgical and physical therapy procedures. However, when one or more elements constituting the musculoskeletal system enter the chronic exacerbation process due to after-traumatic disease, chronic stress, and aging, the functional range of the musculoskeletal system is reduced, and the normal function of the musculoskeletal system, such as decreased muscle mass, decreased bone density, decreased peripheral blood flow, etc. Motor function gradually deteriorates through positive feedback in such a way that structural elements necessary for functional implementation deteriorate, and eventually, various risks are exposed and the quality of life is greatly reduced.

Unexamined Patent Publication No. 10-2019-0044823

Existing approaches for improving motor function that are chronically aggravated due to traumatic aftereffects, certain diseases, and aging include exercise therapy, diet, and drug therapy, but none of these methods are satisfactory in terms of efficiency, economics, and side effects. It doesn't come up with a decent solution. This is because, in order to efficiently restore the reduced motor function, it is necessary to recover the muscle mass, bone density, blood vessel, nervous system and immune system, which are essential for the smooth functioning of the musculoskeletal system, but there is no solution in this dimension.

Accordingly, the present inventors recognized the need for a more integrated approach in a method for improving motor function through recovery of musculoskeletal function, and studied a motor function improvement model linked with musculoskeletal function as shown in FIG. 1 . According to FIG. 1, essential physical elements that the musculoskeletal system must have for smooth movement functions of the human body, including the ability to walk upright, were analyzed into three categories: strength, flexibility, and sense of balance of musculoskeletal tissue. When any one of these three factors worsens, the function of the musculoskeletal system gradually deteriorates in a way that adversely affects the other factors, resulting in a rapid decline in motor function. Therefore, for the efficient recovery of motor function, a method that can improve these three factors in a virtuous cycle is required. As a result of a careful analysis of the physiological factors that aggravate these three factors, the present inventors found that the direct causal relationship with these three factors is the largest factor, including the three factors of decreased neurotransmission function, excessive immunity and poor blood circulation, and these three factors. Cellular stress, a more fundamental factor that contributes to sustaining and amplifying It has been concluded that there is a need for the development of an edible composition suitable for overcoming these four (1+3) factors in a convenient and safe manner and a method of ingestion thereof (FIG. 2).

Accordingly, the present inventors intend to provide a composition and product that can be expected to improve the motor function of humans, especially those aged 60 years or older, by exhibiting the overall improvement effect on the musculoskeletal system by easily ingesting it with confidence.

In order to achieve the above object, the present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient.

The present invention provides a composition for enhancing or improving motor function by improving at least one of musculoskeletal tissue, flexibility, and sense of balance.

The present invention provides a composition for enhancing or improving athletic function by improving muscle mass and bone density.

In addition, the present invention provides a product for enhancing or improving exercise function comprising the composition.

The composition and product containing phlorotannin as an active ingredient of the present invention are safe and easy to use as a natural material, and improve the musculoskeletal tissue, flexibility and sense of balance, which are three aspects essential for the smooth functioning of the musculoskeletal system by using a small amount. It has the effect of enhancing and improving motor function. Compositions and products containing phlorotannin as an active ingredient of the present invention are particularly effective in improving muscle mass and/or bone density.

1 shows a model for improving motor function linked to a musculoskeletal system function.
Figure 2 shows the organic relationship between the process of deterioration of motor function due to the weakening of the musculoskeletal system and related factors.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient. The present invention provides a composition that can enhance or improve motor function through the recovery of musculoskeletal function. The present invention provides a composition that enhances and improves motor function through improvement of three aspects essential for smooth functioning of the musculoskeletal system: musculoskeletal tissue, flexibility, and sense of balance.

When the cellular stress in the tissues constituting the musculoskeletal system increases beyond a threshold due to factors such as post-traumatic sequelae, chronic fatigue of the musculoskeletal system, and aging, the most important stem cells (Satellite cells in the case of muscle; satellite cells in the case of bone) As NFkB, a redox-sensitive transcriptional factor in mesenchymal stem cells, is activated, the stem cell niche/microenvironment required to replace damaged tissues through normal differentiation of stem cells is disturbed. As a result, the oxidative stress in the musculoskeletal system increases, the regeneration rate is reduced compared to the decomposition rate of muscle and bone tissue, the blood flow decreases, and the dehydration of cells occurs.

The present inventors effectively break this vicious cycle and while seeking an effective method for generating a virtuous cycle, the process of the vicious cycle of musculoskeletal function degradation, from the cause-providing step (increased cellular stress), to the biochemical risk amplification step (excessive immune activity) increase) and physiological risk (decreased peripheral blood flow) and physical function decline (muscle reduction, bone density decrease, neurotransmitter function decrease) were classified into 4 stages, and effective reversal of each stage was performed for the reduced musculoskeletal system. It was identified as an essential factor for restoring function.

The present inventors have discovered that a composition containing phlorotannins having various structures and activities as an active ingredient can achieve this purpose while searching for a component having this effect among natural ingredients that are harmless to the human body. That is, it was confirmed that the composition containing phlorotannin as an active ingredient can improve the overall function of the musculoskeletal system, that is, the motor function, and completed the present invention. In particular, it was confirmed that the composition containing phlorotannin as an active ingredient can solve senile sarcopenia and completed the present invention.

The composition of the present invention is a phlorotannin composition optimized for cellular stress reduction activity, immune balance tuning activity, blood circulation promoting activity and neurotransmission promoting activity, and simultaneously provides the three elements of motor function, musculoskeletal tissue, flexibility, and balance, without side effects. can be improved within. The composition of the present invention can improve the function of the musculoskeletal system by improving at least one of muscle mass and bone density, in particular, both muscle mass and bone density, and, as a result, can improve motor function. The composition of the present invention can improve the motor function of the elderly by simultaneously improving the muscle mass and bone density of the elderly, particularly those aged 60 years or older.

The composition of the present invention can exhibit further effects by ingesting the composition in the form of an aqueous solution under specific conditions (concentration, intake amount, time of intake).

Phlorotannin included in the composition for improving motor function by restoring musculoskeletal function of the present invention can be obtained by any conventional method, can be synthesized using commercially available reagents, and can be obtained by extraction and separation from natural products, especially seaweed. may be

Phlorotannin, an active ingredient of the composition of the present invention, can be extracted from brown algae, specifically rhubarb (Eisenia bicyclis), Eisenia arborea (Eisenia arborea), Eisenia desmarestioides (Eisenia desmarestioides), children Eisenia galapagensis, Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, sea bamboo (Ecklonia maxima), Ecklonia radiata (Ecklonia radiata), Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exas Ecklonia exasperta, Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia murati ( Ecklonia muratii), Ecklonia radicosa, Ecklonia richardiana, and Ecklonia wrightii may be extracted from at least one selected from the group consisting of.

As the active ingredient of the composition of the present invention, the phlorotannin compound is preferably an Ekcol-based compound represented by the following Chemical Formula 1-12 among the phlorotannin compounds. Ekcol-based compounds have a relatively small molecular weight, and have a three or five fused ring system, with a hard and flat planar structure, and di-hydroxyphenyl or tri-hydroxyphenol ( Because it can have various conformations through free rotation of tri-hydroxyphenyl) groups, various physiological activities can be exhibited according to the specific structure of each compound in various tissues of the human body.

The phlorotannin compound, which is an active ingredient of the composition of the present invention, may more preferably be at least one compound selected from compounds represented by the following Chemical Formulas 1 to 12.

[Formula 1]

[Formula 2]

[Formula 3]

[Formula 4]

[Formula 5]

[Formula 6]

[Formula 7]

[Formula 8]

[Formula 9]

[Formula 10]

[Formula 11]

[Formula 12]

The composition for improving exercise function of the present invention may contain 0.001-100% by weight of the phlorotannin compound, preferably 0.1-100% by weight. The composition for improving exercise function of the present invention may contain 0-99.999% by weight of water.

In particular, the composition of the present invention contains at least one phlorotannin selected from Chemical Formula 7, which is excellent in cell stress reducing activity, and Chemical Formula 1 to 6, which is excellent in promoting immune balance and blood circulation, and Chemical Formulas 8 to 12, which is excellent in neurotransmission promoting activity. When one or more phlorotannins selected from among are combined, a more excellent effect can be exhibited.

The composition for improving motor function of the present invention is preferably one or more phlorotannins selected from the phlorotannins of Chemical Formula 7 and Chemical Formulas 1 to 6, and one or more phlorotannins selected from the phlorotannins of Chemical Formulas 8 to 12. When rotannin is included in 5-50%, 15-65%, and 10-50% by weight, respectively, cellular stress reduction activity, immune balance promoting activity, blood circulation promoting activity, and neurotransmission promoting activity necessary for recovery of musculoskeletal system function are simultaneously and synergistic. It can exert its effect in a negative way, resulting in improvement of motor function.

The composition for improving exercise function of the present invention comprises 15 to 40% by weight of phlorotannin of Formula 2, 5 to 50% by weight of phlorotannin of Formula 7, and 10 to 50% by weight of phlorotannin of Formula 10 with respect to the total weight In this case, the cellular stress reduction activity, immune balance promotion and blood circulation promoting activity, and neurotransmission promoting activity required for the recovery of musculoskeletal system function simultaneously and synergistically exert their effects, resulting in improvement of motor function.

The composition for improving exercise function of the present invention is 1 to 35% by weight of phlorotannin of Formula 1, 1 to 50% by weight of phlorotannin of Formula 2, 1 to 50% by weight of phlorotannin of Formula 3, with respect to the total weight of the composition for improving exercise function of the present invention Phlorotannin 0.5 to 10% by weight of Formula 5, 0.5 to 10% by weight of phlorotannin of Formula 5, 0.5 to 10% by weight of phlorotannin of Formula 6, 15 to 65% by weight of phlorotannin of Formula 7, Formula 8 Phlorotannin 0.1 to 20% by weight, phlorotannin 0.1 to 20% by weight of Formula 9, phlorotannin 1 to 30% by weight of Formula 10, phlorotannin 1 to 20% by weight of Formula 11, and fluoro of Formula 12 If 0.1 to 20% by weight of tannins are included, it may bring about an effect of improving exercise function.

When the composition of the present invention is ingested as an aqueous solution, the effect may be excellent. In particular, the composition of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably 10 to 200 mL, preferably 50 to 200 mL, in an aqueous solution of 1-100 ppm at a concentration of 20 to 50 ° C. When ingested, the esophagus, small intestine, Absorption in the entire gastrointestinal tract, including the large intestine, is accelerated, improving the musculoskeletal system function, thereby improving motor function.

The composition for improving exercise function of the present invention can be consumed on an empty stomach or with food and beverages and after a meal, but it is more effective when taken on an empty stomach, particularly right after waking up in the morning, and in the rest of the body, such as just before going to bed in the evening.

The present invention provides a product for enhancing or improving exercise function comprising the composition for improving exercise function.

The product for improving exercise function containing the phlorotannin may be commercialized in the form of a liquid, powder, effervescent tablet, protein bar, capsule, etc., but is not limited thereto. In particular, when the product for improving exercise function containing phlorotannin of the present invention is provided in liquid form and ingested, or in powder or effervescent tablet form and dissolved in water, absorption in the gastrointestinal tract is promoted and musculoskeletal function is provided. can improve motor function as a result. In addition, when the product for improving exercise function containing phlorotannin of the present invention is provided in the form of a protein bar or capsule, it is preferable to consume it with sufficient water to promote absorption.

The product of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably 10 to 200 mL, preferably 50 to 200 mL, in an aqueous solution of 1-100 ppm at a concentration of 20 to 50 ° C. When ingested, the esophagus, small intestine, large intestine Absorption in the entire gastrointestinal tract of the back is promoted, thereby improving the function of the musculoskeletal system, thereby improving the motor function.

The product of the present invention contains at least one selected from the group consisting of protein, glycosidal saponin, inositol, glucomanan, dextrin, amino acids, inorganic salts and vitamins as an auxiliary component together with a composition for improving exercise function containing phlorotannin. If it is further included, it is possible to improve the musculoskeletal system function.

The daily usage of phlorotannin contained in the composition and product for improving exercise function of the present invention is preferably about 0.1 to 100 mg based on a 50 kg adult, but the usage is not limited to the above range.

The product for improving motor function of the present invention can improve muscle mass, bone density, flexibility and sense of balance when ingested in a liquid form containing 1 to 100 ppm of phlorotannin compound, 10 to 2000 mL, preferably 50 to 500 mL per day. have.

Hereinafter, the present invention will be described in more detail through examples. However, the following examples are for explaining the present invention in more detail, and the scope of the present invention is not limited by the following examples. The following examples can be appropriately modified and changed by those skilled in the art within the scope of the present invention.

Example 1. Preparation of phlorotannin compound

In order to prepare a composition containing phlorotannin as an active ingredient of the present invention, it was extracted from Ecklonia cava , a brown algae collected near Jeju Island, by the following method.

Ecklonia cava was washed with distilled water to remove foreign substances, dried in the shade, and crushed. Put 5 kg of Ecklonia cava in an extraction container, 20 times the weight of Ecklonia cava, 30% by weight aqueous solution of alcohol was added, and extracted under reflux at 75 to 80° C. for 4 hours to obtain an extract. The extract was filtered through a 10 μm filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a primary extract concentrate. The primary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 1700 g of the primary extract.

The primary extract was dissolved in hot water at 50° C., adsorbed to an adsorption resin, washed with water, and eluted with alcohol to obtain a phlorotannin eluate. The eluate was filtered through a 1 μm filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a secondary extract concentrate. The secondary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 300 g of the secondary extract.

The secondary extract was dissolved in alcohol, and filter aid (diatomaceous earth or bentonite) was added and filtered to obtain an eluate. The eluate was filtered through a 1 µm filter, and the filtered eluate was concentrated under reduced pressure in a water bath at 55°C to obtain a concentrate. The concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 190 g of a tertiary extract.

The tertiary extract obtained above was loaded on liquid chromatography to proceed with compound separation to obtain 104 g, 18 g and 33 g of phlorotannin fractions I, II and III, respectively. At this time, each of the three fractions obtained was dissolved in 60% methanol, filtered with a 0.2 μm membrane filter paper, and loaded into high performance liquid chromatography. In high-performance liquid chromatography, the column was HP ODS Hypersil, the solvent was distilled water and methanol, and the solvent supply was a linear gradient from 15% to 70% methanol for 30 minutes at a flow rate of 1.0ml/min Then, compounds of Formulas 1 to 12 were obtained, which were identified by NMR or the like. The dry weight of the separated compound is shown in Table 1 below.

Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 Formula 7 Formula 8 Formula 9 Formula 10 Formula 11 Formula 12 weight 20.0 26.1 17.9 14.8 9.0 8.4 13.9 4.4 4.7 14.8 3.7 3.2

Example 2. Preparation of a composition comprising a phlorotannin compound

Cell stress reduction activity, immune balance tuning activity, blood circulation promoting activity and neurotransmission promoting activity for the compounds of Formulas 1 to 12 were measured as follows.

Cell stress-reducing activity: The effect on ER Stress, which refers to stress at the cellular level, was measured. To the SH-SY5Y cell line treated with a compound of Formulas 1 to 12 at a concentration of 10 μM for 1 hour, 1000 nM of Thapsigargin, which is well known to cause apoptosis by ER stress, was added and treated for 24 hours, then MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution treatment (2h, 37℃, 5% CO2) was used to measure formazan production at 540 nm, and the degree of apoptosis relief for each compound was measured.

Immune balancing activity: Aging is accompanied by chronic inflammation and disrupts the immune balance. Biochemically, since NFkB, an inflammation-inducing transcription factor, is chronically activated and induces degeneration of musculoskeletal tissue, the degree of activation of NFkB was measured. RAW 264.7 macrophage cell line was transfected with NFkB-Luc reporter plasmid (Clontech, Shiga, Japan), treated with 10 μM of each compound of Formula 1-12 for 1 hour, and then treated with LPS (1 μg/mL) for 24 hours. By measuring luciferase activity, NFkB activation was measured.

Blood circulation promoting activity: Aging causes the tendency of blood to overcoagulate and physiologically decreases blood circulation, thereby reducing homeostasis of musculoskeletal tissue and contributing to degeneration. Therefore, aPTT, a representative index of blood coagulation rate, was measured. After mixing 10 μL of each of the compounds of Formulas 1 to 12 at a concentration of 100 μM in citric acid-treated normal human plasma (90 μL), the mixture was left at 37° C. for 1 minute. Then, after adding 100 μL of aPTT assay reagent (Fisher Diagnostics, USA), it was left at 37° C. for 1 minute, and then 20 mM CaCl 2 (100 μL) was added to measure the time (seconds) required for coagulation.

Neurotransmission-promoting activity: Acetylcholine, a neurotransmitter, is required to trigger the movement of musculoskeletal tissue, and acetylcholine is insufficient in the nerves of aging tissues. Therefore, the inhibitory activity on acetylcholine hydrolase (AChE) that degrades acetylcholine was measured. In DTNB (5,5'-dithiobis(2-nitrobenzoic acid) solution (900μL of 5.55mM DTNB in 50mM potassium phosphate buffer, pH 7.4), ATCh (Acetylthiocholine chloride) solution (2mM ATCh, 25μL) and 1mM concentration of Formula 1~ After mixing 20 μL of each compound of 12, AChE (0.005 unit in 75 μL buffer) was added to cause an enzymatic reaction, and the change in absorbance at 412 nm was measured for 60 seconds to measure the inhibitory activity on AChE.

For each item, the measured activity from the lowest to the highest was standardized on a scale from 1 to 10 and shown in Table 2. Chemical formulas 1 to 6 showed high scores in immunobalancing activity and blood circulation promoting activity, Chemical formula 7 in cellular stress reducing activity, and Chemical formula 8 to 12 in neurotransmission promoting activity, respectively. Compositions 1 to 9 were prepared by mixing the compounds in various ratios (Table 3).

Cell stress reduction activity Immune balancing activity Blood circulation promotion activity Neurotransmission-promoting activity Formula 1 2 8 10 One Formula 2 4 10 9 One Formula 3 4 10 9 One Formula 4 5 10 7 One Formula 5 4 8 7 One Formula 6 3 7 8 One Formula 7 10 5 5 5 Formula 8 4 5 3 7 Formula 9 4 3 3 9 Formula 10 5 2 3 10 Formula 11 2 One 3 8 Formula 12 3 One 3 8

composition 1 composition 2 composition 3 composition 4 composition 5 composition 6 composition 7 composition 8 composition 9 Formula 1 30 20 10 15 Formula 2 50 20 15 30 10 15 Formula 3 50 10 10 10 Formula 4 5 5 Formula 5 5 Formula 6 5 Formula 7 100 50 50 40 25 30 Formula 8 10 5 Formula 9 10 5 Formula 10 100 30 20 30 10 30 Formula 11 20 10 5 Formula 12 5 Sum 100 100 100 100 100 100 100 100 100

Example 3. Preparation of products containing phlorotannin

Each of the prepared compositions and dextrin were mixed in a weight ratio of 1:99 to prepare Product Examples 1 to 9 each containing 1% of Compositions 1 to 9. Since all the compositions had no particular taste, but had a pale yellow color, a small amount of caramel pigment was added to the dextrin to prepare a placebo product (Comparative Product Example 1) in which walking and taste were indistinguishable from the composition.

Experimental Example 1. Effect of improving motor function in the elderly

100 seniors 65 years of age or older were asked to consume 500mL of a beverage containing product examples and comparative examples daily for 4 weeks, and bone density (T-Score) and muscle mass (%FFMI: Fat-Free Muscle Index) before and after intake. , lower extremity flexibility (left flexion) and balance ability (unilateral standing) were measured.

After measuring the height and weight to determine the changes in bone density (T-score) and muscle mass (%FFMI) of the subjects, it was measured using Dual Energy X-ray Absorptiometry (DEXA). As the equipment, Lunar prodigy (GE medical systems, Waukesha, Wisconsin, U.S.A) was used.

Lower extremity flexibility (left flexion: Sit & Reach Flexibility Test) was measured as follows. Sit on a 40 cm high measuring table with both feet spread 5 cm apart, and push the Trunk Flexion Tester to the maximum. Shaking the upper body, the body was not bent forward by the recoil, and the knee was kept straight during measurement. Also, the tip of one hand was placed on the same line as the tip of the other, and when the upper body was bent forward, the head was placed between the arms. The unit was 0.1 cm, and the best record was selected as a result of three measurements.

To measure balance ability, a uni-legged test was performed. The one-legged test can quantitatively measure postural balance and is a convenient method (Rossiter-Fornoff, Wolf, Wolfson, Buchner & FICSIT Group, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 50( 6), M291 -M297 (1995), in this study, the leg was lifted backward, the knee joint was bent at 90 degrees, both eyes were open, and the time until the foot of the raised leg touched the ground was measured. A total of two measurements were taken and the highest record was used.

Preparation and intake method of test drink: Every evening, put Product Examples 1 to 9 or Comparative Product Example 1 into a 500 mL thermos in the amount of one pre-supplied plastic spoon (700 mg capacity), and put it at 40-50 ° C. 500mL of mineral water was added, the lid was closed, and completely dissolved by shaking. Immediately after waking up the next day, 150 mL was taken on an empty stomach, a total of 200 mL was freely ingested between meals, and the remaining 150 mL was taken on an empty stomach before bedtime. The temperature of the solution at the time of ingestion was in the range of 25-40 °C. The results are shown in Table 4 below.

As a result of the test, it was confirmed that in all of the cases of ingestion of Product Examples 1 to 9, the improvement effect was exhibited in all items of muscle mass, bone density, left flexion and unilateral standing compared to the comparative product example. In particular, by confirming that the compositions 7, 8, and 9 (Product Examples 7, 8, 9) exhibit the most excellent effect, the improvement effect of musculoskeletal tissue, flexibility and balance, which are three elements of motor function, by the combination of specific phlorotannin It was confirmed that a synergistic effect appeared in

Product example 1 Product example 2 Product example 3 Product example 4 Product example 5 Product example 6 Product example 7 Product example 8 Product example 9 T-Score 3.0 4.0 2.2 5.9 8.6 5.2 15.0 16.1 14.2 %FFMI 3.0 7.0 5.0 8.7 7.3 7.7 10.3 14.3 13.0 left bend 2.7 4.6 4.2 5.4 6.4 6.0 7.5 8.6 8.6 unicorn 6.6 3.7 11.9 7.3 17.0 14.1 25.9 26.8 25.0 total improvement 15.3 19.3 23.3 27.2 39.3 33.0 58.7 65.8 60.8

Experimental Example 2. Effect of improving trunk muscle function according to intake method (solution and capsule)

For 20 male university male weightlifters aged 19-22 years, composition 8 was administered in 3 concentrations of aqueous solution (1ppm, 20ppm and 100ppm, 200mL ingestion at a time, aqueous solution temperature 15~25℃) and capsules (90mg per capsule, 1 time) 2 capsules were taken in the form of 200mL of room temperature water (15~25℃) every day for 7 days immediately after waking up and right before going to bed, and the improvement of trunk muscle function compared with before intake was evaluated.

To measure trunk muscle function, Humac NORM (CSMi Co., U.S.A) was used, and in order to obtain a more accurate value prior to measurement, it was sufficiently explained to the study subjects so that they could familiarize themselves with the measurement method in advance. Warm-up exercises were performed freely for ~10 minutes. In order to prevent inappropriate movement of the body during measurement, the chest, pelvic, and knee were firmly fixed using a strap, a belt, and a fixed pad. Gravity reduction was performed so that gravity caused by the body mass was not reflected during measurement, and the range of motion (ROM) during measurement was extended from -10°¡Æ to flexion 60°. was set to Trunk flexion and extension strength were measured 4 times at 30°/sec, 4 times at 60°/sec, and 4 times at 90°/sec, and peak torque (Nm) was measured per body weight (%BW). did. Adaptation exercises were performed 4 times for each angular velocity, and the rest time between measurements was set to 20 seconds.

The measurement results are shown in Table 5. When ingested as a solution, it showed superior effects than when ingested in capsule form. Also, the improvement increased as the concentration of the composition increased when the solution was ingested, but after 20 ppm, the improvement showed a tendency to slow. Therefore, it can be seen that ingesting the composition of the present invention as an aqueous solution having a concentration of about 1 to 100 ppm is significantly superior in terms of not only the effect but also the economy compared to ingesting it in the form of a capsule.

Intake product 1ppm solution, 400mL 20ppm solution, 400mL 100ppm solution, 400mL 90mgcapsules x 4 Daily intake of composition 9 0.4 mg 8 mg 40mg 360mg Trunk flexion maximum couple @30 degrees/sec 19.7 25.3 27.4 15.3 Trunk extension maximum force @30 degrees/sec 18.8 23.1 24.9 14.2 Trunk flexion maximum force @60 degrees/sec 19.1 24.7 22.2 13.4 Trunk extension maximum force @60 degrees/sec 10.8 17.4 21.3 9.2 Trunk flexion maximum force @90 degrees/sec 22.6 27.9 29.0 15.3 Trunk extension max. force @90 degrees/sec 21.5 29.3 31.3 16.4 total improvement 112.5 147.7 156.1 83.8

Experimental Example 3. Flexibility improvement effect according to intake method

Forty male college students aged 19-23 years, ingested Composition 9 immediately after waking up in the morning and just before going to bed in the evening for 3 days in 4 different ways (aqueous solution and capsule form of 3 different doses and concentrations) for a total daily intake of 10mg The effect of improving lower extremity flexibility (left flexion) was compared with that without intake.

The results are shown in Table 6 below. As a result of the measurement, when ingested in capsules, there was little effect even if the same amount was ingested. When compared between the solution intake methods, when ingested at a concentration of 25-50 ppm at a single dose, when ingested at a dose of 100-200 mL, the effect was significantly superior to that of a small intake (100 ppm, 50 mL) at a high concentration. Therefore, it was found that in order to give the maximum effect when ingesting the composition, it is more effective to distribute the composition evenly throughout the gastrointestinal tract rather than locally administering the composition at a high concentration in the gastrointestinal tract.

Total daily intake (mg) 10.0 10.0 10.0 10.0 10.0 Concentration of composition in aqueous solution (ppm) 100 50 33.3 25 Capsules with 5mg Serving amount (mL) of aqueous composition 50 100 150 200 Take with 150mL of water Improvement rate of left anterior flexion compared to before intake (%) 12.8 22.7 27.5 20.8 2.3

Experimental Example 4. Effect of improving exercise function according to the time of intake

For women aged 65 and over, with a wash-out period of one week, product example 7 drinks (25ppm concentration, total 300mL) were administered in two ways for one week each - (1) A total of two times during the daytime (1 time between breakfast and lunch) , between lunch and dinner) and (2) immediately after waking up in the morning + in the evening right before going to bed - twice a time, 150mL each was taken, and the improvement in motor function compared to before intake was evaluated. The results are shown in Table 7. As a result, the case of method (2) showed a superior improvement effect. Therefore, it was found that the injection of the composition into the gastrointestinal tract during the resting period of the human body is more effective than that during the active period.

improvement % Intake mode 1 Intake Mode 2 strength (grip strength) 4.6 12.1 Flexibility (left flexion) 5.8 9.6 Balance ability (standing on one leg with eyes open) 3.7 8.8 total improvement 14.1 30.5

Claims (17)

A composition for improving exercise function comprising a phlorotannin compound as an active ingredient. The composition for improving motor function according to claim 1, wherein at least one of musculoskeletal tissue, flexibility, and sense of balance is improved. The composition for improving exercise function according to claim 1, wherein at least one of muscle mass and bone density is improved. The composition for improving exercise function according to claim 1, wherein the phlorotannin compound is at least one selected from phlorotannins represented by the following Chemical Formulas 1 to 12.
[Formula 1]

[Formula 2]

[Formula 3]

[Formula 4]

[Formula 5]

[Formula 6]

[Formula 7]

[Formula 8]

[Formula 9]

[Formula 10]

[Formula 11]

[Formula 12]

The composition for improving musculoskeletal function according to claim 1, wherein the composition comprises 0.001-100% by weight of a total phlorotannin compound. The method according to claim 4, wherein the composition comprises at least one selected from phlorotannins represented by Chemical Formulas 1 to 6, and at least one selected from phlorotannins represented by Chemical Formula 7, and Chemical Formulas 8 to 12. A composition for improving motor function, characterized in that it. The method according to claim 1, wherein the phlorotannin compound is rhubarb (Eisenia bicyclis), Eisenia arborea (Eisenia arborea), Eisenia desmarestioides (Eisenia desmarestioides), Eisenia galapagensis (Eisenia galapagensis), Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, sea bamboo (Ecklonia maxima), Ecklonia radiata, Ecklonia bicyclis ( Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exasperta, Ecklonia pasti Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia muratii, Ecklonia radicosa radicosa), Ecklonia richardiana (Ecklonia richardiana) and Ecklonia wrightii (Ecklonia wrightii) composition for improving musculoskeletal system, characterized in that extracted from at least one selected from the group consisting of. The composition for improving exercise function according to claim 1, wherein 10 to 200 mL of the phlorotannin compound is ingested at a time in an aqueous solution of 20 to 50 °C with a concentration of 0.1 to 100 ppm. The composition for improving exercise function according to claim 8, wherein the aqueous solution is taken on an empty stomach. The composition for improving exercise function according to claim 1, wherein the daily usage of the phlorotannin compound is 0.1 to 100 mg based on a 50 kg adult. A product for improving motor function comprising the composition for improving motor function of claim 1. The product for improving exercise function according to claim 11, wherein the product is in the form of a liquid, powder, effervescent tablet, or protein bar. The product for improving exercise function according to claim 11, wherein 10 to 200 mL of the phlorotannin compound is ingested at a time in an aqueous solution at 20 to 50°C with a concentration of 0.1 to 100 ppm. The product for improving exercise function according to claim 11, wherein the daily usage of the phlorotannin compound contained in the product is 0.1 to 100 mg based on a 50 kg adult. The product for improving exercise function according to claim 11, wherein 10 to 2000 mL of the phlorotannin compound is ingested in a liquid form containing 1 to 100 ppm per day. The product for improving exercise function according to claim 15, wherein the liquid is consumed on an empty stomach. The product for improving exercise function according to claim 11, wherein at least one of muscle mass and bone density is improved.

Images